RecruitingNCT06717334

A Study of Lung Cancer Screening in People With Unexplained Weight Loss

Enrichment of Lung Cancer Screening Through Unexplained Weight Loss (UWL) to Stage Shift and Improve Survival

Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

409 participants

Start Date

Dec 2, 2024

Study Type

OBSERVATIONAL

Conditions

Lung Cancer Screening

Summary

The researchers are doing this study to see if people with unexplained weight loss who have lung cancer screening are more likely to have or develop lung cancer than people without unexplained weight loss. The lung cancer screening will involve use of low-dose computed tomography (LDCT), a CT scan that gives off very low doses of radiation and can make detailed pictures of the lungs to help find tumors. The study researchers will also analyze participants' blood samples to determine if blood testing can be used to help to diagnose lung cancer.

Eligibility

Min Age: 50 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is examining whether people who have experienced unexplained weight loss and are eligible for lung cancer screening should undergo a low-dose CT (LDCT) lung scan. Unexplained weight loss can be an early warning sign of cancer, and this study aims to see if it identifies more lung cancer cases earlier. **You may be eligible if...** - You are 50–80 years old with at least a 20 pack-year smoking history (e.g., 1 pack/day for 20 years) - You have lost 3–10% of your body weight without a clear medical explanation in the past 18 months - Your life expectancy is greater than 1 year **You may NOT be eligible if...** - You are pregnant or trying to become pregnant - You have had a chest CT scan in the past 12 months - You have a prior history of non-small cell lung cancer - You are currently undergoing cancer treatment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTLow Dose CT imaging

at baseline and at Year 1.

OTHERblood draws

at baseline and at Year 1.

OTHERscreening questionnaire

at baseline and at 1 year after registration.

Locations(8)

Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)

Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth (All Protocol Activities)

Middletown, New Jersey, United States

Memorial Sloan Kettering Bergen (All Protocol Activities)

Montvale, New Jersey, United States

Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities)

Commack, New York, United States

Memorial Sloan Kettering Westchester (All Protocol Activities)

Harrison, New York, United States

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, United States

Montefiore Health Systems (Montefiore Medical Center)

The Bronx, New York, United States

Memorial Sloan Kettering Nassau (All Protocol Activities)

Uniondale, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06717334

Related Trials

LUNG-07: Advancing Precision-Based Lung Cancer Screening: Implementation, AI-Guided Risk Stratification, and Biomarker Integration (CREST AI)

NCT074085312 locations

Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Lung Cancer

NCT070086641 location